The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: COR Therapeutics, Key Pharmaceuticals
Approval Status: Approved May 1998
Treatment for: For the treatment of acute coronary syndrome
General Information
For the treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, Integrilin has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
Clinical Results
For the treatment of patients undergoing PCI. In this setting, Integrilin has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.
